Previously, impaired BRCA1/2 genes have been known to play an important role in conferring sensitivity to PARP1 inhibitors, providing a well-accepted DNA repair mechanism for the tumor-suppressive effect of PARP1 inhibitors [3, 7, 31, 32]. The gene discussed is BRCA1; the disease is neoplasm.